Jennison Associates
PTCT icon

Jennison Associates’s PTC Therapeutics PTCT Stock Holding History

Jennison Associates’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-100,000
Closed -$984K – 659
2017
Q1 		$984K Buy
+100,000
New +$1.21M ﹤0.01% 576
2015
Q4 		– Sell
-300,000
Closed -$8.01M – 727
2015
Q3 		$8.01M Buy
+300,000
New +$12.8M 0.01% 519

Other funds holding PTCT

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates's PTCT Position: Q3 2016 in Review

Jennison Associates sold out of PTC Therapeutics (PTCT) in Q3 2016, closing a stake of 446,000 shares — an estimated $3.13M sold.

Jennison Associates first reported a position in PTCT in Q3 2013 and held it in 7 quarters. The position peaked at $33.2M in Q4 2015. 115 funds tracked by Wall St. Rank hold PTCT as of Q3 2016.

  • Jennison Associates reported no remaining PTC Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Jennison Associates sold 446,000 PTC Therapeutics shares in Q3 2016, an estimated $3.13M.
  • Jennison Associates first reported a position in PTC Therapeutics in Q3 2013 and held it in 7 quarters.
  • Jennison Associates's PTC Therapeutics position peaked at $33.2M in Q4 2015.
  • 115 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2016.

Based on Jennison Associates's 13F filing for Q3 2016, filed 1 Nov 2016.